Summary.-Evidence is presented that microscopic tumours (of a transplantable murine mammary carcinoma, M8013X) grow faster than larger, palpable, tumours. Microscopic tumours are also more radiosensitive than larger tumours. The decrease in radiosensitivity in larger tumours is prevented to a large extent by misonidazole, which has no significant effect on the radiosensitivity of microscopic tumours. The retardation in growth rate which occurs after the fast microscopic growth is probably related to the appearance of hypoxic cells. Both the decrease in growth rate and the progressive development of hypoxia may be caused by the relatively poorer blood flow in larger tumours. Part of the radioresistance in "large" tumours (-250 mm3) seems to be due to factors other than hypoxia; maybe cell-kinetic factors also play a role. The intrinsic radiosensitivity of tumour cells in microscopic tumours was assessed by means of a modified latency test: the Dq and Do were 2*2 and 2*5 Gy respectively. A number of factors which may influence the reliability of these estimates are discussed.
THE METABOLIC CONDITIONS and cellkinetic characteristics of a tumour appear to change during its different growth phases. This has been suggested as having important repercussions on the effectiveness of anti-tumour agents such as ionizing radiation and hyperthermia. The effects of irradiation on a tumour would be influenced by the oxygenation status and the cell kinetics. Some evidence already exists that anoxic cells are absent from very small tumours and only appear during further growth (Suit et al., 1960; Reinhold & de Bree, 1968; Shipley et al., 1975 Shipley et al., , 1976 Fu et al., 1976; Stanley et al., 1978) . It is very difficult to assess directly the influence of the cell kinetics of a tumour on its response to irradiation. (Fletcher, 1971 (Fletcher, , 1972 Newton & Spittle, 1969; Schueren, 1979) . The success of such types of treatments could be due to the relatively small number of cells to be inactivated, but would still be enhanced by a possible higher radiosensitivity of the tumour cells in early phases of growth.
In this study the radiosensitivity of a microscopic tumour is tested by means of a modified latency test (Clifton & Draper, 1963; Alfieri & Hahn, 1978) . Moreover, the effects of the anoxic-cell sensitizer misonidazole (MISO) are studied. In this way information is obtained about the changes in radiosensitivity and the time of appearance of hypoxic cells during growth of a transplantable murine mammary carcinoma in vivo. Apart from the theoretical interest this would have practical implications, as it could provide guidelines on whether or not to test the possible usefulness of anoxic cell sensitizers for the radiotherapy of subclinical disease.
MATERIALS AND METHODS
The M8013 tumour originated in 1950 as a mammary adenocarcinoma in a castrated oestrogen-stimulated male C57BL mouse at the NKI (Nederlands Kanker Instituut) (Van Dongen, 1961) . The M8013X is a line derived from this tumour, which is kept by serial transplantation in male DBA2 x C57BL10 mice (obtained from the Centraal Proefdieren Bedrijf TNO, Zeist, Netherlands). The volume-doubling time of the M8013X tumour is 16-1-8 days. In most experiments described in this study, tumour implantation was performed by s.c. injection of small volumes, with a microlitre syringe, of a cell suspension in the right hind leg of 8-12-weekold mice. To obtain a cell suspension, an aseptically excised tumour was minced thoroughly with scissors in 25 ml Eagle's minimum essential medium supplemented with 100 i.u./ml penicillin. The resulting cell suspension was separated from the tumour debris and the number of cells was counted, using lyssamine green exclusion as a test for viability. If necessary, the suspension was concentrated by centrifugation (8 min, 120 g ) to a final concentration of 1-4 x 106 cells/ml. The cell yield was 2-4% (assuming 5 x 108 cells/g of tumour tissue; Steel, 1977 The numbers of animals per group were: irradiated 1 day after implantation, with or without MISO, 9; 4 days, 9; 7 days, 30; 10 days, 20; 12 days, 9; 14 days, 9; 13 days with MISO, 9; 13 days without MISO, 5. The error bars represent s.e.
volume is -250 mm3. A significant drop in radiosensitivity is found after about 10 days. The decrease in radiosensitivity is prevented largely, but not completely, by MISO. Tumour growth delay caused. by irradiation can be correlated with the relative survival of tumour cells, using a "titration" curve as in Fig. 2 (Alfieri & Hahn, 1978; Haveman et al., 1980) . In this way the "intrinsic" radiosensitivity of the (microscopic) tumours can be assessed. In a titration curve it is shown that implanting lower cell numbers leads to an increase in tumour growth delay. Irradiation of a tumour leads to a reduction in cell number and the extra time which is required by a tumour to grow to a certain volume after irradiation can be used to estimate this reduction in cell number, by matching it, on a titration curve, with the extra tumour growth time due to implantation of a certain lower cell number. In this way survival curves can be obtained, as shown in Fig. 3 . The titration curves in Fig. 2 show also that:
(1) When lower cell numbers are implanted, some of the injected mice failed to develop a tumour ("no take") and when "no takes" occur the titration curve deviates from the straight line which can be drawn through the data points with 100% takes.
(2) The tumour growth time to a certain volume not only depends on the number of cells implanted, but also on the site of the implantation.
(3) From the slope of the curve of tumour growth time against the logarithm of the number of implanted cells, a doubling time of 2*0 days is obtained. This doubling time does not differ significantly for the different sites of implantation. From the measurements of tumour volume during exponential growth on the leg or the back, a doubling time of 1-6-1-8 days is obtained, which is slightly shorter than the value from a "titration" curve. Owing to the occurrence of "no takes" at lower cell numbers in a titration curve, the dose range in the survival curves (Fig.  3) which can be studied is limited. Moreover, the deviation from the straight line when lower cell numbers are implanted has to be taken into account. Titration curves were repeated for each independent experiment shown in Fig. 3 (10 animals per treatment group).
The tumour growth time to 1 cm3 varies slightly between experiments; starting from 105 cells injected s.c. into the leg, the mean value is (19 independent experiments, 10 animals each) 14-4 days, standard deviation 1-7 days.
When M8013X cells were "titrated" on the leg of pre-irradiated mice (5 Gy total body 3 days before implantation) the tumour growth times and the slope of the resulting curve did not differ significantly from a titration curve on animals without treatment; "no takes" however appeared only at lower numbers of cells injected.
As shown in Fig. 3 , no significant differences can be found in radiation sensitivity, whether the cells were irradiated before implantation or 4 h, 3 days and 10 days after implantation of 3 x 104 cells. The same curve fits the data of Fig. 3(a) and (b). The data in Fig. 3 confirm those from the independent experiment shown in Fig. 1 . The decrease in radiosensitivity at Day 10 in Fig. 1 is not, however, as clear in Fig. 3(b) ; this may be due to the spread in the data, or to slight variations in growth time to a certain tumour volume, starting with 3 x 104 cells in independent experiments. Dose-response curves, with and without MISO, for tumours with a volume 250 mm3 are shown in Fig. 4(a) . In Fig. 4(b) the data of Fig. 4(a) are redrawn so that they may be compared with the (Fig. 4(b) ) are 2-2 and 2-5 Gy respectively, and for 250-mm3 tumours without MISO 4-5 and 7 0 Gy, and with MISO 2-8 and 3-7 Gy respectively.
DISCUSSION
Microscopic tumours of M8013X appear to be significantly more radiosensitive than the (macroscopic) palpable tumours. The relatively low radiosensitivity of the large tumours can be enhanced considerably by MISO. Very probably the radioresistance of the large tumours is thus at least in part the result of the progressive development of hypoxia in the tumour during growth. Large tumours, even in the presence of MISO, are more radioresistant than microscopic tumours (Fig. 4(b) ). This may be due to cell-kinetic effects; as the fraction of actively proliferating cells could be decreased in these large tumours. The dose-response curve (Fig. 4) for 250mm3 tumours shows that these are more radioresistant than microscopic tumours, even at low doses. The effect of the hypoxic cell sensitizer is also evident at lower doses. This is very probably because the hypoxic cell fraction in these 250mm3 tumours is very large. In the mean time, we found that effects due to hypoxia in larger tumours were further enhanced by the Nembutal anaesthesia (Wondergem et al., 1981) . Similar effects of Nembutal (for other tumours) have been described by Denekamp et al. (1979) . The progressive development of hypoxia during growth (Fig. 1) is presumably due 30 min before irradiation. 9-10 animals per treatment group. In (b) the data are replotted in such a way that tumour growth delay in palpable tumours can be compared with the assumed relative survival of microscopic tumours. The dashed curve is redrawn from Fig. 3. to the relatively insufficient vascularization of the tumour, compared to the tumour growth rate. This apparently becomes evident at a certain tumour volume. (When in our experiments the tumours start to be palpable, tumour volume < 50 mm3.)
The fact that the growth time to a certain tumour volume is dependent on the site of implantation may be caused by differences in lag time before cells start to grow at the different sites, or by differences in take efficiency of the cells. A certain fraction of cells may be lost upon implantation, depending on the site of implantation. In the experiment shown in Fig. 2 the tumour growth time to 1 cm3 on the leg and the back differs by 4-5 days (i.e. 2-2-2-8 doubling times) which may mean that the take efficiency on the back is 15-20% of that on the leg.
It is important to consider differences in tumour growth time at different sites. For our experiments on the radiosensitivity of microscopic tumours, implantation of tumour cells was done as far as possible on the same site on the lower leg, using a small inoculum (25 pl).
In Fig. 3 the intrinsic radiosensitivity of tumour cells in microscopic tumours is assessed. A number of factors may limit the reliability of an estimation of the radiosensitivity in this way, the method described may give a fair estimate for microscopic tumours, but possibly not for larger palpable tumours.
(1) The slightly longer doubling time obtained from a "titration" curve (Fig. 2 ) may lead to a slight underestimation of the radiosensitivity, as a doubling time of 1*7 days may be taken as more realistic.
(2) Irradiation of tumours may lead to fast regrowth (Van Peperzeel, 1970) , an effect which is difficult to evaluate in this model; again, a false estimate of the radiosensitivity using the "titration" curve may be the result. However, accelerated regrowth after irradiation probably does not play an important role in microscopic tumours, which must be supposed to grow already relatively fast (see below).
(3) The error due to cell-kinetic effects during microscopic growth is apparently not very large; there are no significant changes in radiosensitivity during the first 7 days after inoculation.
(4) Effects due to irradiation of the tumour-bed, in the dose range studied, are probably not very large; there is no significant difference in apparent relative survival of cells irradiated before or after implantation (Fig. 3) nor are there any significant differences in tumour growth delay during the first 7 days after inoculation (Fig. 1) .
(5) Cell loss, which may occur in large tumours, is probably negligible in microscopic tumours.
"Large" (250mm3) tumours (Fig. 4a ) are more radioresistant than the microscopic tumours even at low doses, and there is no clear break in the dose-response curve (Jansen, 1980; Wondergem et al., 1981) ; possibly the hypoxic cell fraction in these tumours is at least 500o.
It has to be postulated that the doubling time during microscopic growth is much shorter than during macroscopic growth. Even when it is assumed that all cells injected contribute to growth, the tumour growth time to 1 cm3 on the leg (1 cm3 (Van Peperzeel, 1970) . From the slope of the curve of tumour growth time against the logarithm of the number of implanted cells (Fig. 2) , a doubling time of 2-0 days is obtained. The fact that the doubling time from the slope of the titration curve is in excess of 1-7 days probably means that microscopic exponential growth when a smaller number of cells is inoculated is dominated only for a limited time by the fast growth, a relatively large part of the microscopic growth already occurring with the doubling time of macroscopic growth, when a smaller number of cells is inoculated. Another possibility is that lower cell numbers lead to a longer lag phase before cell proliferation starts.
The retardation of growth rate which occurs after the fast microscopic growth is probably related to the appearance of a hypoxic cell fraction, as assessed in Fig. 1 .
In conclusion, it can be said that our results further confirm that small tumours are more radiosensitive than larger ones. In larger tumours (with > 3 x 107 cells in this model) the radioresistance may be explained at least in part by the presence of hypoxic cells, as the radioresistance can be largely removed by MISO. Other, such as cell-kinetic, factors are not excluded as large tumours, even in the presence of hypoxic-cell sensitizer, are more radioresistant than microscopic tumours. Microscopic tumours grow faster than larger tumours, the retardation in growth rate occurring after the fast microscopic growth being very probably related to the appearance of hypoxic cells, probably caused by a relatively poor blood flow in larger tumours. The method of relating implanted cell numbers with tumour growth time can be used to obtain an estimate of the intrinsic radiosensitivity of tumour cells in vivo over a limited dose range. Fraction sizes normal to clinical practice are well within the dose range studied. However, one should be aware of a number of factors which may limit the direct applicability of the method to larger palpable tumours.
